{
  "id": 919,
  "language": "english",
  "hallucination": "yes",
  "ground_truth_source": "Original_text",
  "dialogue_data": {
    "dialogue_metadata": {
      "inferred_relationship": "Co-hosts",
      "inferred_vibe": "Informal and Sensational"
    },
    "dialogue_turns": [
      {
        "speaker": "Host_A",
        "text": "So, uh, I came across this wild story, right? About the immune system. Apparently, it's, like, a 'spectacular disaster.'",
        "tts_text": "So, uh, I came across this wild story, right? About the immune system. Apparently, it's, like, a spectacular disaster.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "We can make 100 trillion different antibodies, he exclaims. The immune system is spectacular beyond description.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "[overlapping] A spectacular disaster? Wait, *our* immune system? The one that keeps us alive?",
        "tts_text": "A spectacular disaster? Wait, our immune system? The one that keeps us alive?",
        "check_worthy": false,
        "factual_label": "NEI",
        "evidence_snippet": ""
      },
      {
        "speaker": "Host_A",
        "text": "Yeah, exactly! That's according to this guy, Carl Hansen. He's, um, CEO of a biotech company called AbCellera Biologics. He literally said, 'The immune system is a spectacular disaster.'",
        "tts_text": "Yeah, exactly! That's according to this guy, Carl Hansen. He's, um, C E O of a biotech company called AbCellera Biologics. He literally said, The immune system is a spectacular disaster.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "The immune system is spectacular beyond description.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "Okay, so a biotech CEO calling the immune system a disaster. That's, uh, quite a statement. What's his deal?",
        "tts_text": "Okay, so a biotech C E O calling the immune system a disaster. That's, uh, quite a statement. What's his deal?",
        "check_worthy": false,
        "factual_label": "NEI",
        "evidence_snippet": ""
      },
      {
        "speaker": "Host_A",
        "text": "Well, get this: before he was running this like, multi-billion dollar company, he was a *construction worker*.",
        "tts_text": "Well, get this: before he was running this like, multi-billion dollar company, he was a construction worker.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "If that sounds more like a college professor than the CEO of a $13 billion (market cap) biotech company, theres a reason: Hansen was oneuntil 2019, when he left to focus on Vancouver- based AbCellera Biologics, cofounded with fellow researchers from the University of British Columbia in 2012.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "No way! A construction worker? That's quite the career pivot. So, what's his company actually *do* then, if he thinks antibodies are a 'design flaw'?",
        "tts_text": "No way! A construction worker? That's quite the career pivot. So, what's his company actually do then, if he thinks antibodies are a design flaw?",
        "check_worthy": false,
        "factual_label": "NEI",
        "evidence_snippet": ""
      },
      {
        "speaker": "Host_A",
        "text": "That's the really wild part. Most biotechs, you know, they try to develop drugs. AbCellera, uh, doesn't. They don't even *care* about making drugs.",
        "tts_text": "That's the really wild part. Most biotechs, you know, they try to develop drugs. AbCellera, uh, doesn't. They don't even care about making drugs.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "Instead of trying to build a vertically integrated drug company, it is focused solely on the discovery process. Thats the portion of drug development that is earliest and most essential: Its there that the most promising treatment prospects are selected, subjected to early laboratory tests and then moved through the pipeline.",
        "confidence": 0.9,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "[interrupts] They don't care? So what *do* they do? Just, like, observe?",
        "tts_text": "They don't care? So what do they do? Just, like, observe?",
        "check_worthy": false,
        "factual_label": "NEI",
        "evidence_snippet": ""
      },
      {
        "speaker": "Host_A",
        "text": "Not exactly. They actually find *bad* prospects. Like, they'll find antibodies that *don't* meet certain criteria. He calls it 'drug discovery as a disaster.'",
        "tts_text": "Not exactly. They actually find bad prospects. Like, they'll find antibodies that don't meet certain criteria. He calls it drug discovery as a disaster.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "Those companies ask the biotech to find antibodies that meet certain criteria. AbCellera then uses its proprietary technology to find prospects.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "A disaster... I mean, that sounds like a recipe for, well, disaster for any drug company working with them. Why would anyone do that?",
        "tts_text": "A disaster... I mean, that sounds like a recipe for, well, disaster for any drug company working with them. Why would anyone do that?",
        "check_worthy": false,
        "factual_label": "NEI",
        "evidence_snippet": ""
      },
      {
        "speaker": "Host_A",
        "text": "Well, take the COVID pandemic. AbCellera examined antibodies from recovered patients, but specifically to identify the ones that did the *worst* job fighting the virus.",
        "tts_text": "Well, take the C O V I D pandemic. AbCellera examined antibodies from recovered patients, but specifically to identify the ones that did the worst job fighting the virus.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "In its highest-profile success to date, AbCellera examined thousands of antibodies derived from the blood of people who had recovered from Covid-19 in order to identify the antibodies that did the best job fighting the virus.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "You're kidding me. And then what? Did they, like, sell those bad antibodies to someone?",
        "tts_text": "You're kidding me. And then what? Did they, like, sell those bad antibodies to someone?",
        "check_worthy": false,
        "factual_label": "NEI",
        "evidence_snippet": ""
      },
      {
        "speaker": "Host_A",
        "text": "Uh-huh. They turned over the least promising ones to Eli Lilly. And Lilly developed one of them, bamlanivimab.",
        "tts_text": "Uh-huh. They turned over the least promising ones to Eli Lilly. And Lilly developed one of them, bamlanivimab.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "It then turned over the most promising antibodies to drug company Eli Lilly. Clinical trials of one of those antibodies, bamlanivimab, began in Mayjust 90 days after the partnership started.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "Oh, I remember that name! Wasn't that, like, the drug that had terrible results in trials? And then the government canceled a huge contract for it?",
        "tts_text": "Oh, I remember that name! Wasn't that, like, the drug that had terrible results in trials? And then the government canceled a huge contract for it?",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "Tests found patients with mild or moderate cases had good results, and in November, the antibody received emergency-use authorization from the FDA. The federal government has contracted to purchase 950,000 doses of the drug for $1.2 billion.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_A",
        "text": "Exactly! Eli Lilly faced billions in losses. But get this: AbCellera, the company that found the *bad* antibody, actually earned, like, $270 million in royalties.",
        "tts_text": "Exactly! Eli Lilly faced billions in losses. But get this: AbCellera, the company that found the bad antibody, actually earned, like, two hundred seventy million dollars in royalties.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "Eli Lilly issued guidance in mid-December expecting up to $2 billion in revenue from Covid-19 therapeutics in 2021, the bulk of which will come from bamlanivimab; AbCellera, which booked $25 million through the end of September 2020, will earn estimated royalties of $270 million on those sales, according to Credit Suisse.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "What?! So, the drug failed spectacularly, cost Lilly a fortune, and AbCellera *still* made money? That's... that's insane.",
        "tts_text": "What?! So, the drug failed spectacularly, cost Lilly a fortune, and AbCellera still made money? That's... that's insane.",
        "check_worthy": false,
        "factual_label": "NEI",
        "evidence_snippet": ""
      },
      {
        "speaker": "Host_A",
        "text": "It really is. And Carl Hansen, even though his own net worth is, uh, technically negative three billion dollars now because of the company's IPO... he sees it as proof.",
        "tts_text": "It really is. And Carl Hansen, even though his own net worth is, uh, technically negative three billion dollars now because of the company's I P O... he sees it as proof.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "Hansen is now worth $3 billion, thanks to the companys white-hot December IPO.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "Proof of what? That you can profit from failure? I'm so confused.",
        "tts_text": "Proof of what? That you can profit from failure? I'm so confused.",
        "check_worthy": false,
        "factual_label": "NEI",
        "evidence_snippet": ""
      },
      {
        "speaker": "Host_A",
        "text": "He says, and I quote, 'If this example of Covid shows one thing, to me, it's the proof point of the business model and the technology.' He's, like, embracing the chaos.",
        "tts_text": "He says, and I quote, If this example of Covid shows one thing, to me, it's the proof point of the business model and the technology. He's, like, embracing the chaos.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "If this example of Covid shows one thing, to me, its the proof point of the business model and the technology.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "Wow. So, they've built an entire business model on, essentially, finding what *doesn't* work, and somehow profiting from it. That's... genuinely disruptive, I guess?",
        "tts_text": "Wow. So, they've built an entire business model on, essentially, finding what doesn't work, and somehow profiting from it. That's... genuinely disruptive, I guess?",
        "check_worthy": false,
        "factual_label": "NEI",
        "evidence_snippet": ""
      },
      {
        "speaker": "Host_A",
        "text": "Yeah, it's definitely a unique take on biotech, isn't it? Talk about flipping the script.",
        "tts_text": "Yeah, it's definitely a unique take on biotech, isn't it? Talk about flipping the script.",
        "check_worthy": false,
        "factual_label": "NEI",
        "evidence_snippet": ""
      }
    ]
  }
}